Kerendia (finerenone) is the first drug in its class to show a benefit ... Bayer is running an open-label study – CONFIRMATION-HF – testing Kerendia with Jardiance in patients hospitalised ...
Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...
GlobalData’s analysis starts in the year the FDA expanded the Jardiance label. Back then ... s stem cell therapy Revascor and Bayer’s Kerendia as other promising prospects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback